Lilly shares safety, tolerability data on its next-generation obesity drug – statnews.com & more related News Here
Lilly shares safety, tolerability data on its next-generation obesity drugstatnews.com Lilly’s triple agonist, retreutide, significantly improved weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential in the treatment of obesity and its complications.investors.lilly.com Eli Lilly says next-generation obesity drug curbs sleep apnea, among other benefitsreuters A new wave of weight loss…
